Abbott Seeks Expanded Labeling For CardioMEMS HF Monitor Based On GUIDE HF Results
Executive Summary
The GUIDE HF investigators contend the trial missed its primary endpoint because of COVID-19.
You may also be interested in...
Abbott Hopes To Prevent Heart Failure Hospitalizations With New CardioMEMS HF Labeling
The FDA expanded the indication for Abbott’s CardioMEMS HF wireless heart failure monitor to include patients who have never been hospitalized for heart failure before.
Cardiovascular Catch-Up: J&J RF Balloon Ablation; Biotronik Home Monitor; And More
September has been full of cardiovascular technology news, including announcements from Biotronik and Biosense Webster. Here are a few of the highlights.
Abbott Launches NeuroSphere Virtual Clinic For Remote Neurostim Programming
The US FDA approved Abbott's system that allows physicians to communicate with patients and remotely program their neuromodulation device.